ANGPT2 and wet macular degeneration: For example, faricimab that simultaneously targets VEGF and angiopoietin-2 was recently approved, not because it was superior to aflibercept alone but because Phase III trials of DME and wet AMD showed non-inferiority to anti-VEGF [43,44].